Cryo-Cell International, Inc. Quarterly report pursuant to Section 13 or 15(d)

Notes Payable (Tables)

9 Months Ended

Aug. 31, 2023

As of August 31, 2023 and November 30, 2022, the note payable obligation was as follows:


	August 31, 2023			November 30, 2022
Note payable - Susser	$	8,805,747		$	8,921,437
Unamortized debt issuance costs - Susser		(174,776	)		(191,035	)
Net note payable	$	8,630,971		$	8,730,402
Current portion of note payable	$	162,659		$	150,527
Long-term note payable, net of debt issuance costs		8,468,312			8,579,875
Total	$	8,630,971		$	8,730,402

Interest expense on the note payable for the three and nine months ended August 31, 2023 and 2022 was as follows:


	For the three months ended		For the nine months ended
	August 31, 2023		August 31, 2023
Interest expense on notes payable - Susser	$	200,638	$	607,319
Debt issuance costs - Susser		5,396		16,258
Total interest expense	$	206,034	$	623,577


	For the three months ended		For the nine months ended
	August 31, 2022		August 31, 2022
Interest expense on notes payable - TCB	$	370	$	18,485
Interest expense on notes payable - Susser	$	89,585	$	89,585
Debt issuance costs - TCB		592		10,368
Total interest expense	$	90,547	$	118,438